$CLRB
Cellectar Biosciences, Inc.

2017 Q2 Form 10-Q Financial Statement

#000114420417026247 Filed on May 11, 2017

View on sec.gov

Income Statement

Concept 2017 Q2 2017 Q1 2016 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.040M $960.0K $1.210M
YoY Change -24.09% 0.0% 51.25%
% of Gross Profit
Research & Development $2.176M $1.857M $1.440M
YoY Change 124.32% 78.64% 50.0%
% of Gross Profit
Depreciation & Amortization $100.0K $86.91K $90.00K
YoY Change 11.11% -4.25% 0.0%
% of Gross Profit
Operating Expenses $2.176M $1.857M $2.650M
YoY Change -6.61% 78.64% 49.72%
Operating Profit -$3.216M
YoY Change
Interest Expense $4.941K $3.387K $60.00K
YoY Change 201.83% 516.94% -97.81%
% of Operating Profit
Other Income/Expense, Net $94.94K -$79.09K
YoY Change -52.53% -102.8%
Pretax Income -$3.120M -$2.890M -$2.590M
YoY Change 46.48% -452.44% -372.63%
Income Tax
% Of Pretax Income
Net Earnings -$3.122M -$2.891M -$2.590M
YoY Change 46.35% -450.65% -372.63%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$2.311M -$0.24 -$3.453M
COMMON SHARES
Basic Shares Outstanding 13.46M shares 12.84M shares 5.368M shares
Diluted Shares Outstanding 12.01M shares

Balance Sheet

Concept 2017 Q2 2017 Q1 2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.310M $11.24M $11.44M
YoY Change 4.92% 488.48% 196.37%
Cash & Equivalents $8.368M $11.24M $11.50M
Short-Term Investments
Other Short-Term Assets $1.030M $950.0K $750.0K
YoY Change 368.18% 179.41% 127.27%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $9.340M $12.19M $12.19M
YoY Change 14.74% 444.2% 191.63%
LONG-TERM ASSETS
Property, Plant & Equipment $1.580M $1.420M $1.440M
YoY Change 1.94% -13.41% -16.69%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $10.00K $10.00K $10.00K
YoY Change 0.0% 0.0% -15.77%
Total Long-Term Assets $3.260M $3.110M $3.130M
YoY Change 0.62% -6.61% -8.38%
TOTAL ASSETS
Total Short-Term Assets $9.340M $12.19M $12.19M
Total Long-Term Assets $3.260M $3.110M $3.130M
Total Assets $12.60M $15.30M $15.32M
YoY Change 10.72% 174.69% 101.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.470M $1.190M $1.420M
YoY Change 79.27% 95.08% 108.82%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $90.00K
YoY Change -100.0% -100.0% -64.0%
Total Short-Term Liabilities $1.590M $1.400M $1.630M
YoY Change 14.39% -50.18% -71.4%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $10.00K
YoY Change -100.0% -100.0% -88.89%
Other Long-Term Liabilities $140.0K $150.0K $150.0K
YoY Change -6.67% 0.0% 0.0%
Total Long-Term Liabilities $140.0K $149.9K $151.8K
YoY Change -12.5% -16.73% -36.74%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.590M $1.400M $1.630M
Total Long-Term Liabilities $140.0K $149.9K $151.8K
Total Liabilities $1.740M $1.548M $1.785M
YoY Change 12.26% -48.21% -70.0%
SHAREHOLDERS EQUITY
Retained Earnings -$73.68M -$70.79M
YoY Change 9.57%
Common Stock $135.00 $104.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $10.86M $13.75M $13.54M
YoY Change
Total Liabilities & Shareholders Equity $12.60M $15.30M $15.32M
YoY Change 10.72% 174.64% 101.64%

Cashflow Statement

Concept 2017 Q2 2017 Q1 2016 Q4
OPERATING ACTIVITIES
Net Income -$3.122M -$2.891M -$2.590M
YoY Change 46.35% -450.65% -372.63%
Depreciation, Depletion And Amortization $100.0K $86.91K $90.00K
YoY Change 11.11% -4.25% 0.0%
Cash From Operating Activities -$2.660M -$2.987M -$2.350M
YoY Change 40.0% 64.14% 57.72%
INVESTING ACTIVITIES
Capital Expenditures -$250.0K $66.30K -$60.00K
YoY Change 200.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$250.0K -$66.30K -$60.00K
YoY Change 200.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -10.00K $2.848M 8.210M
YoY Change -100.13% -2290.39% 183.1%
NET CHANGE
Cash From Operating Activities -2.660M -$2.987M -2.350M
Cash From Investing Activities -250.0K -$66.30K -60.00K
Cash From Financing Activities -10.00K $2.848M 8.210M
Net Change In Cash -2.920M -$206.2K 5.800M
YoY Change -148.5% -89.42% 317.27%
FREE CASH FLOW
Cash From Operating Activities -$2.660M -$2.987M -$2.350M
Capital Expenditures -$250.0K $66.30K -$60.00K
Free Cash Flow -$2.410M -$3.054M -$2.290M
YoY Change 26.84% 67.79% 55.78%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
145367 USD
CY2016Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
146583 USD
CY2017Q1 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
4520 USD
CY2016Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
5249 USD
CY2017Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
149887 USD
CY2016Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
151832 USD
CY2017Q1 us-gaap Liabilities
Liabilities
1548380 USD
CY2016Q4 us-gaap Liabilities
Liabilities
1784708 USD
CY2017Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
875572 USD
CY2017Q1 us-gaap Common Stock Value
CommonStockValue
135 USD
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
104 USD
CY2017Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
87427196 USD
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
83451222 USD
CY2017Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-73678350 USD
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-70787026 USD
CY2017Q1 us-gaap Stockholders Equity
StockholdersEquity
13748981 USD
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
13539872 USD
CY2017Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15297361 USD
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15324580 USD
CY2017Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
55000 USD
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
55000 USD
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1039454 USD
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
961254 USD
CY2016Q1 us-gaap Costs And Expenses
CostsAndExpenses
2000708 USD
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2000708 USD
CY2016Q1 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
2824722 USD
CY2016Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
549 USD
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
824563 USD
CY2016Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2825271 USD
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1856880 USD
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
955356 USD
CY2017Q1 us-gaap Costs And Expenses
CostsAndExpenses
2812236 USD
CY2017Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3387 USD
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-2891324 USD
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-79088 USD
CY2017Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
86911 USD
CY2016Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
90773 USD
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
165674 USD
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
102918 USD
CY2017Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-230341 USD
CY2016Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-67256 USD
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
199616 USD
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-55793 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2987437 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1818256 USD
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
66301 USD
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-66301 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
0 USD
CY2017Q1 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
655 USD
CY2016Q1 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
588 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2847513 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-131160 USD
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-206225 USD
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1949416 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3857791 USD
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1908375 USD
CY2017Q1 us-gaap Interest Paid
InterestPaid
364 USD
CY2016Q1 us-gaap Interest Paid
InterestPaid
1467 USD
CY2017Q1 clrb Reverse Stock Split Fractional Shares
ReverseStockSplitFractionalShares
0 USD
CY2016Q1 clrb Reverse Stock Split Fractional Shares
ReverseStockSplitFractionalShares
594 USD
CY2017Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 USD
CY2016Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
69450 USD
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
104106 shares
CY2017Q1 clrb Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Unvested Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedOutstandingNumber
404627 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
104106 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
19.84
CY2017Q1 clrb Share Based Compensation Arrangement By Share Based Payment Award Options Non Vested Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedExercisableWeightedAverageExercisePrice
3.94
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
19.84
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
54579 USD
CY2017Q1 clrb Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue
167134 USD
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
54579 USD
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y8M12D
CY2017Q1 clrb Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingWeightedAverageRemainingContractualTerm
P9Y2M1D
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y8M12D
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
471433 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
37300 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.59
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.18
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
508733 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.19
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
0 shares
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0
CY2017Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
950882 USD
CY2016Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2017Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
8760446 shares
CY2017Q1 clrb Number Of Shares Reserved For Future Issuance
NumberOfSharesReservedForFutureIssuance
9269179 shares
CY2016 clrb Number Of Shares Reserved For Future Issuance
NumberOfSharesReservedForFutureIssuance
12321724 shares
CY2017Q1 dei Document Type
DocumentType
10-Q
CY2017Q1 dei Amendment Flag
AmendmentFlag
false
CY2017Q1 dei Document Period End Date
DocumentPeriodEndDate
2017-03-31
CY2017Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2017Q1 dei Entity Registrant Name
EntityRegistrantName
Cellectar Biosciences, Inc.
CY2017Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001279704
CY2017Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2017Q1 dei Trading Symbol
TradingSymbol
CLRB
CY2017Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
13462170 shares
CY2017Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2017Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2017Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000 shares
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000 shares
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2017Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13458170 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10368325 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10368325 shares
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.24
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.96
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12010284 shares
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
858107 shares
CY2017Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2016Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.91
CY2017Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12010284 shares
CY2016Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
906381 shares
CY2017Q1 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
1216 USD
CY2016Q1 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
325 USD
CY2017Q1 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
2934759 USD
CY2016Q1 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0 USD
CY2017Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
86591 USD
CY2016Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
60528 USD
CY2016Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
55000 USD
CY2017Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
533065 shares
CY2016Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
533065 shares
CY2017Q1 clrb Employee Service Share Based Compensation Nonvested Total Compensation In Current Year
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInCurrentYear
372648 USD
CY2017Q1 clrb Employee Service Share Based Compensation Nonvested Total Compensation In Year Two
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInYearTwo
391798 USD
CY2017Q1 clrb Employee Service Share Based Compensation Nonvested Total Compensation In Year Four
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInYearFour
357 USD
CY2017Q1 clrb Share Based Compensation Arrangement By Sharebased Payment Award Options Unvested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndExpectedToVestOutstandingNumber
3.20 shares
CY2017Q1 clrb Employee Service Share Based Compensation Nonvested Total Compensation In Year Three
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInYearThree
186079 USD
CY2016Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
At a special meeting held on February 8, 2016, the Companys stockholders approved an amendment to the Companys certificate of incorporation to effect a reverse split of the Companys common stock at a ratio between 1:5 to 1:10 in order to ensure that adequate authorized but unissued shares would be available for anticipated future financings, and to satisfy requirements for the continued listing of the Companys common stock on the NASDAQ Capital Market. In addition, the proposal approved by the stockholders provided that if the reverse split was effected, the number of shares of common stock that the Company is authorized to issue remained unchanged at 40,000,000. The Companys stockholders further authorized the board of directors to determine the ratio at which the reverse split would be effected by filing an appropriate amendment to the Companys certificate of incorporation. The board of directors authorized the ratio of the reverse split on February 24, 2016, and effective at the close of business on March 4, 2016, the Companys certificate of incorporation was amended to effect a 1-for-10 reverse split of the Companys common stock (the 2016 Reverse Split). All share and per share numbers included in these consolidated financial statements give effect to the 2016 Reverse Split.
CY2016Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-10 reverse split

Files In Submission

Name View Source Status
0001144204-17-026247-index-headers.html Edgar Link pending
0001144204-17-026247-index.html Edgar Link pending
0001144204-17-026247.txt Edgar Link pending
0001144204-17-026247-xbrl.zip Edgar Link pending
clrb-20170331.xml Edgar Link completed
clrb-20170331.xsd Edgar Link pending
clrb-20170331_cal.xml Edgar Link unprocessable
clrb-20170331_def.xml Edgar Link unprocessable
clrb-20170331_lab.xml Edgar Link unprocessable
clrb-20170331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v466189_10q.htm Edgar Link pending
v466189_ex31-1.htm Edgar Link pending
v466189_ex31-2.htm Edgar Link pending
v466189_ex32-1.htm Edgar Link pending